-

Harmony Biosciences to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences.

Citi's 2025 Global Healthcare Conference

  • Location: Miami, FL
  • Tuesday, December 2, 2025

8th Annual Evercore Healthcare Conference

  • Location: Miami, FL
  • Fireside Chat: Tuesday, December 2, 2025, at 2:35 p.m. ET

Piper Sandler 37th Annual Healthcare Conference

  • Location: New York, NY
  • Fireside Chat: Wednesday, December 3, 2025, at 10:30 a.m. ET

A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.

Contacts

Investor Contact:
Matthew Beck
astr partners
917-415-1750
matthew.beck@astrpartners.com

Media Contact:
Cate McCanless
Harmony Biosciences
202-641-6086
cmccanless@harmonybiosciences.com

Harmony Biosciences

NASDAQ:HRMY

Release Versions

Contacts

Investor Contact:
Matthew Beck
astr partners
917-415-1750
matthew.beck@astrpartners.com

Media Contact:
Cate McCanless
Harmony Biosciences
202-641-6086
cmccanless@harmonybiosciences.com

More News From Harmony Biosciences

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD. The poster presentation details are as follows: Abstract Title Poster Presentation Session Treatment with Pitolisant in Subgroups of Adults with...

Harmony Biosciences to Participate in Upcoming Investor Conferences

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences. Goldman Sachs 47th Annual Global Healthcare Conference Fireside Chat: June 9, 2026, at 8:40 a.m. ET Location: Miami, FL Oppenheimer CNS & Neuro-Muscular Summit Fireside Chat: June 10, 2026, at 3:25 p.m. ET Location: Miami, FL A webcast of the fireside chats will be available on the investor...

Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also...
Back to Newsroom